Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.65 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 10/20 | 0.63 |
| ▸ | CA1 | P00915 | 10/20 | 0.63 |
| ▸ | CA2 | P00918 | 10/20 | 0.63 |
| ▸ | CA4 | P22748 | 10/20 | 0.63 |
| ▸ | CA7 | P43166 | 10/20 | 0.63 |
| ▸ | CA9 | Q16790 | 10/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | SYK | P43405 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | S100A4 | P26447 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6864670 | 1.00 | KMT2A (0.68) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL14349620 | 0.89 | KMT2A (0.55) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL5575433 | 0.89 | TRPV1 (0.66) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL6430735 | 0.88 | CA12 (0.66) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL3263316 | 0.88 | CA12 (0.66) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL1351078 | 0.85 | SYK (0.63) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL1351080 | 0.85 | SYK (0.63) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL13211953 | 0.84 | TRPV1 (0.56) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL13103496 | 0.83 | SYK (0.54) | KMT2ATRPV1TRPM8CA12CA1 | |
| SCHEMBL14376032 | 0.83 | SYK (0.54) | KMT2ATRPV1TRPM8CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392690-A2 | NOVEL PROCESSES FOR THE PREPARATION OF ADENOSINE COMPOUNDS AND INTERMEDIATES THERETO | Aventis Pharma Deutschland GmbH (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030069423-A1 | Novel processes for the preparation of adenosine compounds and intermediates thereto | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-04-10 | — | — | US | disclosed |
| WO-2002091988-A2 | NOVEL PROCESSES FOR THE PREPARATION OF ADENOSINE COMPOUNDS AND INTERMEDIATES THERETO | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069423-A1 | Novel processes for the preparation of adenosine compounds and intermediates thereto | ADK, ADORA2A, ADORA1 | KMT2A 3981/4885TRPV1 3033/4885TRPM8 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.